MULTIPLE MYELOMA

This study is for people with serious blood cancers, immune deficiencies, or genetic disorders who need a stem cell transplant. Researchers are using umbilical cord blood from unrelated donors to see how well the new cells take hold and rebuild healthy blood counts. The goal is t…

This early-phase study tests a new treatment called WS-CART-CS1 for people with multiple myeloma that has come back or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified to target the CS1 protein found on myeloma cells. The …

This phase 2 study tests whether two drugs, teclistamab and talquetamab, can be given safely in an outpatient clinic instead of requiring a hospital stay for people with multiple myeloma. About 100 adults who have already tried other treatments will receive preventive medicines t…

This study looks at whether plasma exchange or newer medicines like daratumumab can help the kidneys recover in people with multiple myeloma who have a type of kidney damage called light chain cast nephropathy. About 450 adults with this condition will be followed for 90 days to …

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or not improved after prior therapy. About 380 participants will be randomly assigned to receive either etentamig or a standard therapy chosen by their doct…

This study tests a combination of four drugs (cyclophosphamide, bortezomib, dexamethasone, and daratumumab) for people with kidney disease caused by abnormal proteins from a blood condition called monoclonal gammopathy. The goal is to see if this treatment is safe and can improve…

This study is for people with a specific genetic subtype of multiple myeloma (t(11;14)) that has come back or stopped responding to treatment. It tests a combination of two drugs, belantamab mafodotin and venetoclax, sometimes with a steroid. The goal is to find the safest and mo…

This study tests a combination of four drugs (bortezomib, isatuximab, cyclophosphamide, and dexamethasone) as an initial treatment for people with multiple myeloma who also have kidney problems and are eligible for a stem cell transplant. The goal is to see how many patients achi…

This early-phase trial tests a combination of three drugs—talquetamab, iberdomide, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and check for side effects. About 32 adults will t…

This early-phase study tests an experimental pill called KTX-1001 in adults with multiple myeloma whose cancer has come back or stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow the disease. About 165 pa…

This study is testing a new combination of two drugs, mezigdomide and elranatamab, in about 62 adults with multiple myeloma that has returned or no longer responds to standard treatments. The main goals are to find the best dose and check for side effects. Researchers will also l…

This early-phase study tests a new treatment called BMS-986453 for people recently diagnosed with multiple myeloma who are not planning a stem cell transplant. The therapy uses specially engineered immune cells to target two proteins on myeloma cells. The main goals are to check …

This study tests a two-step stem cell transplant using lower doses of radiation and chemo before the transplant. The goal is to reduce deaths from the transplant itself while still treating blood cancers like leukemia and lymphoma. About 63 adults will take part. If successful, t…

This study tests whether the drug talquetamab can help people with multiple myeloma who have already received a type of immunotherapy called BCMA CAR T-cell therapy. The goal is to see if adding talquetamab improves response and keeps the cancer from coming back. About 17 adults …

This early-phase study is testing a drug called carfilzomib, combined with standard chemotherapy, to help collect stem cells for a transplant in people with multiple myeloma. The goal is to find the safest and most effective dose. About 18 participants will be enrolled to monitor…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in patients at high risk of rejecting a stem cell transplant. About 8 adults with blood cancers or bone marrow failure will receive the drug before standard transplant preparation. The goal…

This study tests whether two new drug combinations (talquetamab plus pomalidomide or talquetamab plus teclistamab) work better than current standard treatments for multiple myeloma, a blood cancer. About 795 adults with multiple myeloma will be randomly assigned to one of the new…

This study tests whether a combination of elotuzumab, iberdomide, and dexamethasone can improve outcomes for people with multiple myeloma that has returned or not responded to treatment, after they have received a type of CAR T-cell therapy called idecabtagene vicleucel. About 49…

This study tests whether adding isatuximab to lenalidomide after a stem cell transplant can eliminate remaining cancer cells in multiple myeloma patients. About 50 adults who still have detectable cancer after transplant will receive this two-drug maintenance therapy for one year…

This study tests whether a specific diet can improve treatment response and quality of life for people newly diagnosed with multiple myeloma who are receiving standard chemotherapy. Researchers will track participants' quality of life through questionnaires and measure disease ma…

This early-stage trial tests a new drug called venetoclax alongside standard treatments for people with a specific genetic subtype of multiple myeloma (t(11;14)). The goal is to find the safest dose and see if the combination can better control the cancer. About 100 adults with a…

This study tests whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely in an outpatient setting instead of the hospital. It involves 15 patients who have tried at least three prior treatments. The goal is to develop clear procedures for outp…

This early-phase study tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) as a first treatment for people with high-risk multiple myeloma or plasmacytoma. About 20 participants will receive the therapy to see if it is safe and effective, and …

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has returned or not responded to at least four prior treatments. The therapy uses a patient's own immune cells, modified to target a protein on myeloma cells. The g…

This study tests whether combining two drugs (teclistamab or talquetamab with daratumumab) can delay the start of multiple myeloma in people with high-risk smoldering myeloma. About 50 participants will receive one of the two drug combinations. The main goal is to see if the trea…

This study tests a structured health program (PASCA) for adults aged 18-70 with multiple myeloma who have had a stem cell transplant. The program proactively screens for and manages seven common complications like high blood pressure, kidney issues, and chronic pain. Half of the …

This study tests whether switching between two different drug combinations (Dara-RVd and Tec-RVd) is safe and effective for people newly diagnosed with multiple myeloma. About 65 participants will receive alternating cycles of these therapies. The goal is to achieve undetectable …

This study tests a drug called belantamab, alone or with other treatments, in people with multiple myeloma (a type of blood cancer). The goal is to find safe doses and see how well the drug shrinks tumors. About 152 adults who have already tried other therapies will take part.

This study tests a cancer treatment called cilta-cel (Car-T therapy) for people with multiple myeloma. Researchers want to see if using a milder chemotherapy before the infusion works as well as the standard stronger chemo. About 60 participants will be enrolled. The goal is to f…

This study tests a gentle, step-by-step approach to treating multiple myeloma in very frail patients. Instead of starting all drugs at once, treatment begins with just two medications, and a third is added later. The goal is to help patients stick with therapy and improve their q…

This study tests a new treatment called GC012F for people with multiple myeloma that has returned or not responded to at least three prior treatments. GC012F uses a patient's own immune cells, modified to target two proteins (CD19 and BCMA) on myeloma cells, aiming to control the…

This early-stage study tests an experimental drug called ABBV-438 in about 127 adults with multiple myeloma that has returned or stopped responding to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink the cancer. Partici…

This study tests whether people with relapsed multiple myeloma can safely give themselves the drug elranatamab at home instead of going to a clinic. About 20 participants will be trained to self-inject and will track side effects, time spent, and any unplanned hospital visits. Th…

This study tests whether adding a vitamin A derivative (ATRA) to a standard myeloma drug combination (carfilzomib and dexamethasone) can make the cancer respond again in patients whose disease has stopped responding to carfilzomib. About 42 adults with relapsed or refractory mult…

This study tests a new medicine called elranatamab (given as a weekly shot) against standard drug combinations for multiple myeloma that has returned or stopped responding to previous treatments. About 492 adults aged 18 and older who have already tried at least one prior therapy…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for patients who have no other suitable treatment options and cannot join ongoing…

This study tests whether a two-step immunotherapy approach can eliminate remaining cancer cells in people with newly diagnosed multiple myeloma who still have detectable disease after standard treatment. Participants first receive talquetamab, and if that doesn't clear the cancer…

This study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see how many patients respond to the therapy. This is n…

This study tests whether a new drug called cevostamab, combined with two standard drugs (pomalidomide and dexamethasone), works better than the usual treatments for multiple myeloma. About 380 people who have already tried 1 to 3 prior therapies will take part. The goal is to see…

This study tests whether adding the drug teclistamab to standard lenalidomide maintenance therapy can better prevent multiple myeloma from returning after a stem cell transplant. About 1,600 adults with newly diagnosed myeloma who have already responded to initial treatment will …

This study tests several new drug combinations (teclistamab, talquetamab, and JNJ-79635322) in 160 adults aged 18-70 with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The goal is to see if these combinations are safe and work better than standard …

This study tests two new drug combinations (Tec-DR and Tal-DR) against a standard treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if the new combos keep the cancer from growing longer and help more patients ach…

This early-phase trial tests a new type of immunotherapy called CAR T cells in 27 adults with multiple myeloma that has come back or not responded to standard treatments. The therapy uses specially engineered immune cells to target two proteins (BCMA and CD19) on cancer cells. Th…

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a patient's own transplant. About 60 adults with multiple myeloma will receive either the combination or a placebo. The goal is to see if the drug improves stem cell yield and speeds…

This study tests a new drug called etentamig combined with daratumumab against a standard treatment for multiple myeloma, a blood cancer. It is for adults newly diagnosed with the disease who are not healthy enough for a stem cell transplant. The goal is to see if the new combina…

This study tests a new drug called elranatamab, alone or with another drug (daratumumab), in people whose multiple myeloma has returned after at least one prior treatment. About 944 participants will be randomly assigned to one of three treatment groups. The goal is to see if elr…

This study tests a new approach to collecting stem cells for people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma who need a stem cell transplant. The goal is to see if using a standard drug alone, and adding another drug only when needed, can collect enough st…

This study tests a new treatment for people with metastatic cancers (cancers that have spread) that haven't gotten better with standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to better attack the cancer, and then return them t…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. About 80 participants will continue treatment and be monitored for side effects. The goal is to keep providing the drug while c…

This phase 3 study tests whether switching to a new drug called linvoseltamab after initial standard therapy works better than staying on standard therapy alone for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 1000 participants will b…

This study tests the antiviral drug remdesivir for treating RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer or autoimmune treatments. About 60 adults with confirmed RSV infection will receive remdesivir to see if it prevents severe b…

This program provides the experimental drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of standard treatments and cannot join a clinical trial. Patients must get approval from their doctor and local health authorities. The goal…

This study tests a combination of four drugs (daratumumab, carfilzomib, pomalidomide, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see how many patients achieve tumor shrinkage and how long the benefit …

This early-phase study tests a new drug called SHR-3836 in 99 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors. Parti…

This early-phase study tests whether the drug selinexor can help keep multiple myeloma under control after CAR-T cell therapy. About 20 adults with high-risk or hard-to-treat myeloma will take selinexor pills after their CAR-T treatment. The goal is to see if this maintenance app…

This early-stage study tests two drugs—elranatamab (a shot) and iberdomide (a pill)—in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and check for side effects. About 87 adults will take part, receiving the drugs in…

This study is for people newly diagnosed with multiple myeloma. It uses a special test to find tiny amounts of cancer left after treatment. If the test shows no cancer after 6 cycles of drugs, some patients may get more drugs instead of a stem cell transplant. If cancer is still …

This early-stage study tests a cell therapy (arlocabtagene autoleucel) combined with other drugs in people whose multiple myeloma has returned or stopped responding to treatment. About 147 participants will receive different combinations to find safe doses and check if the tumors…

This study tests a personalized approach for people with newly diagnosed multiple myeloma who have had a stem cell transplant. After transplant, participants receive a drug called elranatamab as maintenance therapy, with the dose and duration guided by a sensitive blood test that…

This early-stage study tests a new drug called BL-M24D1 in about 33 adults with multiple myeloma or other blood cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug helps control the disease. Particip…

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares taking the antibody drugs daratumumab or isatuximab continuously versus stopping after about 18 months. The goal is to see if the shorter treatment works just …

This study looks at whether CAR T cell therapy, a type of cancer treatment that uses a patient's own immune cells, can be safely given to people with moderate to severe kidney problems. About 20 adults with certain blood cancers (like lymphoma, myeloma, or leukemia) will receive …

This study tests whether adding cyclophosphamide to elranatamab helps people with relapsed or refractory multiple myeloma who have risk factors that make elranatamab alone less effective. About 26 adults with measurable disease will receive the combination. The main goal is to se…

This study tests whether giving immune globulin infusions regularly can prevent serious infections in adults with multiple myeloma who are receiving a type of immunotherapy called bispecific antibody therapy. About 183 participants will be randomly assigned to receive the infusio…

This study compares two approaches to prevent graft-versus-host disease (GVHD) in 400 people receiving stem cell transplants from unrelated donors for blood cancers like leukemia and lymphoma. One method uses a drug called thymoglobulin, while the other uses a combination of calc…

This study tests two new drug combinations (teclistamab plus daratumumab or lenalidomide) in people aged 65 and older with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if these combos are safe and can shrink the cancer significantly …

This study tests an experimental drug called surzetoclax in people with multiple myeloma that has returned or stopped responding to other treatments. The drug is given alone or with standard therapies to find the best dose and check safety. About 130 adults will take part worldwi…

This study tests whether giving specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, is safe and can help control relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and multiple myeloma. About 80 participants will receive …

This early-phase study tests a new cell therapy (CAR19-BCMA CAR-T) for people with multiple myeloma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The main goal is to check safety an…

This study tests a four-cycle treatment of daratumumab combined with three other drugs (Dara-CyBorD) in 30 people newly diagnosed with multiple myeloma who also have kidney failure. The goal is to see how well the treatment shrinks the cancer and improves kidney function. The stu…

This study tests if a new drug, iberdomide, works better than the current standard lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer pr…

This study is for adults with multiple myeloma that has returned or stopped responding to treatment. Researchers are testing whether giving the drug belantamab mafodotin less often, along with standard cancer medicines, can still control the cancer while causing fewer eye-related…

This early-phase study tests whether adding the drug mezigdomide after CAR T-cell therapy can help keep the cancer-fighting cells active longer in people with multiple myeloma that has returned. About 15 adults who have already tried several treatments will receive mezigdomide pl…

This study tests whether taking iberdomide pills after CAR-T cell therapy can keep multiple myeloma under control longer than simply watching and waiting. About 78 people who have already received the CAR-T treatment idecabtagene vicleucel will be randomly assigned to either take…

This study tests a new drug called cevostamab in 20 Chinese patients whose multiple myeloma has returned or stopped responding to treatment. The goal is to see how the drug moves through the body, if it is safe, and if it can shrink the cancer. This is an early-stage trial, so th…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has returned or not responded to standard therapies. About 18 adults will receive the therapy along with two chemotherapy drugs to prepare the body. The main goal is to c…

This study tests a new type of CAR-T cell therapy (PD-1Ab21-BCMA CAR-T) for people with multiple myeloma who also have kidney problems. The goal is to see if this treatment can keep the cancer from coming back for at least a year after initial therapy. About 25 participants will …

This study is testing whether adding the drug epunamin to a standard chemotherapy regimen (DECP) can help people whose multiple myeloma has come back or stopped responding to treatment. About 48 adults aged 18 to 75 will receive the combination and be monitored for tumor shrinkag…

This study tests an experimental drug called linvoseltamab in people with newly diagnosed multiple myeloma. The drug aims to shrink tumors and improve outcomes. About 149 participants will receive the drug to check safety, side effects, and how well it works.

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with rare cancers that have a specific BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing for at least 24 weeks. About 30 participa…

This study tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can better control multiple myeloma compared to iberdomide alone. About 411 newly diagnosed patients who have already had a stem cell transplant will be randomly assigned to …

This study looks at whether taking a prebiotic (a type of fiber) can improve gut health in people with multiple myeloma or lymphoma after a stem cell transplant. About 30 participants will receive either the prebiotic or a placebo for about 10 days before and during their transpl…

This study tests an experimental drug, etentamig, for multiple myeloma, a blood cancer that often returns or resists treatment. About 440 adults will receive etentamig alone or with other cancer drugs to see if it is safe and works. The goal is to control the disease, not cure it…

This early-stage trial tests a new drug (JNJ-79635322) combined with standard treatments for multiple myeloma, a blood cancer. About 140 adults with myeloma will receive different drug combinations to find the safest and most effective doses. The goal is to control the disease an…

This study looks at a combination of three drugs—daratumumab, pomalidomide, and dexamethasone (Dara-PD)—for people whose multiple myeloma has returned after their first treatment. About 50 adults will take part to see if this combo can delay the next relapse and how well it works…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and helps shrink tumors. About 250 adults who have already tried standard treatments will take part.

This study tests an experimental drug called JNJ-79635322 in people with multiple myeloma that has come back or stopped responding to treatment. Participants must have already tried at least three different types of therapy. The main goal is to see how well the drug shrinks or co…

This early-phase study tests a new therapy using a patient's own immune cells (T cells) trained to attack proteins found on myeloma cells. It includes adults with active multiple myeloma or high-risk precursor conditions (MGUS or smoldering myeloma). The main goals are to find a …

This study looks at whether people with multiple myeloma who have been in a very deep remission (called MRD-negative) for at least two years can safely stop their maintenance therapy. Researchers will follow 70 participants for up to 24 months to see how many remain in remission …

This study tests a new treatment called anitocabtagene autoleucel (a type of cell therapy) against the usual treatments for multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies. About 450 adults will take part. The goal is to see if the new thera…

This study tests whether a new drug combination (belantamab mafodotin with lenalidomide and dexamethasone) can delay cancer growth better than the current standard therapy in people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 520 adults wil…

This study tests a new drug, JNJ-79635322, against another antibody treatment in people with multiple myeloma that has come back or stopped responding after at least three prior treatments. About 400 participants will be randomly assigned to one of the two treatments. The goal is…

This study tests whether adding elranatamab to standard drugs (lenalidomide and dexamethasone) can deeply reduce or eliminate multiple myeloma cells in people newly diagnosed with the disease. About 104 participants will receive the combination and be checked for minimal residual…

This early-phase study is testing whether it's safe and possible to collect a patient's own stem cells and give them together with CAR-T therapy for blood cancers that have come back or not responded to treatment. About 20 adults with cancers like lymphoma, leukemia, or multiple …

This study tests a new drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to other treatments. The goal is to find the best dose and check if it is safe and can shrink the cancer. About 387 participants will take part in this early-phase trial…

This study tests a three-drug combination (isatuximab, lenalidomide, and dexamethasone) at lower-than-standard doses in 50 newly diagnosed multiple myeloma patients who are highly vulnerable to side effects. The goal is to see if the treatment can control the cancer while reducin…

This study tests a combination of three drugs (carfilzomib, iberdomide, and dexamethasone, called KID) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment is safe and how well it works at reducing cance…

This study is for people whose multiple myeloma has returned or stopped responding to standard treatments, including CAR T-cell therapy. Researchers are testing a combination of four drugs (belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone) to see if it can shrin…

This study tests a new drug, AZD0305, alone or with other cancer drugs, in people with multiple myeloma. The goal is to check safety, side effects, and how well it works. About 226 adults with multiple myeloma will take part in this early-phase trial.

This study tests a drug called elranatamab in 33 people with multiple myeloma that has returned or not responded after 1 to 3 prior treatments. The goal is to see if the drug can make cancer cells undetectable in tests. Participants will receive elranatamab alone, and the study w…

This study tests whether adding isatuximab to standard lenalidomide maintenance therapy can better control high-risk multiple myeloma after a stem cell transplant. About 61 adults aged 18-72 with newly diagnosed high-risk myeloma will receive the drug combination. The main goal i…

This early-phase study tests whether a personalized cancer vaccine (made from a patient's own cells) combined with the drug elranatamab is safe and feasible for people with multiple myeloma that has returned or not responded to prior treatments. Up to 25 adults with at least thre…

This early-stage study tests a new treatment called KSVCBD injection for people with multiple myeloma that has come back or not responded to prior therapies. The treatment is a type of CAR-T cell therapy given directly into the body to target cancer cells. The main goals are to c…

This study tests whether a drug called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels caused by their cancer treatment. About 100 participants will either receive IgPro20 or standard care, and researchers will compare infection ra…

This study tests an experimental pill called LP-118 in up to 100 adults with blood cancers that have come back or not responded to treatment. The main goal is to find a safe dose and see how the body processes the drug. Early signs of effectiveness will also be tracked, but this …

This program offers a special cell therapy called cilta-cel to people with multiple myeloma who have run out of standard options. The treatment is made from the patient's own immune cells and is given when other therapies are not possible. It is only for those with serious or lif…

This study is for people with multiple myeloma who have been on maintenance therapy for at least two years after a stem cell transplant and have no detectable cancer (minimal residual disease negative). The goal is to see if it's safe to stop maintenance drugs without the cancer …

This early-phase trial tests a new treatment called AZD0120 for adults with multiple myeloma, a type of blood cancer. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and CD19). The main goals are to check safety and find the right dose, …

This study looks at whether a diet that combines longer overnight fasting with a Mediterranean eating pattern is practical for people with multiple myeloma or its precursor conditions (MGUS or smoldering myeloma). Researchers will enroll 120 participants to test if people are wil…

This early study tests a new treatment using donor immune cells (CAR T cells) designed to find and attack a protein called BCMA on multiple myeloma cancer cells. It is for adults whose cancer has returned or not responded to at least two prior treatments. The main goals are to ch…

This study tests whether a new drug called GR1803 works better than the current standard combination (daratumumab, pomalidomide, and dexamethasone) for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior treatments. About 358 participants will…

This study is for people with multiple myeloma that has come back or stopped responding to other treatments. The trial has two parts: first, finding the best dose of a drug called belumosudil mesylate, and second, testing that dose alone or with dexamethasone to see if it can con…

This early-phase study tests whether a low-dose radiation and chemotherapy combination can safely prepare multiple myeloma patients with kidney problems for CAR T cell therapy (Carvykti). Standard prep often excludes these patients due to kidney risks. The study enrolls 16 adults…

This study is testing a new drug, CC-92480, combined with other therapies for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink tumors. About 260 participants will take part in this…

This early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion vaccine) to standard CAR-T cell therapy is safe and works better for people with multiple myeloma that has returned or not responded to treatment. About 25 adults will receive the vaccine alon…

This program gives people with multiple myeloma access to a personalized cell therapy (ide-cel) that didn't meet commercial standards but may still work. It's for patients whose own batch of cells was made but couldn't be sold, and who are stable enough to receive it. The goal is…

This study tests several new drug combinations for people with multiple myeloma, a type of blood cancer. It aims to see if these treatments are safe and how well they work. About 200 participants will join, and the study can add new treatments as they become available. The goal i…

This study tests a combination of a stem cell transplant and a special immune cell therapy (C-CAR088) for people with a very aggressive form of multiple myeloma that didn't respond well to initial treatment. The goal is to see if this two-step approach is safe and can better cont…

This study tests whether a new combination of drugs (elranatamab, daratumumab, and lenalidomide) works better than the standard treatment for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The new combo uses a targeted therapy that h…

This study tests a personalized treatment approach for elderly patients (65+) newly diagnosed with multiple myeloma. The treatment is adjusted based on each patient's frailty level to improve effectiveness and reduce side effects. About 131 participants will receive a combination…

This study is for people with high-risk multiple myeloma who have completed initial treatment. It compares two maintenance therapies: a combination of ixazomib plus a reduced dose of lenalidomide versus ixazomib alone. The goal is to see which approach better delays cancer progre…

This study tests whether adding targeted radiation to a drug called talquetamab can safely and effectively treat multiple myeloma that has spread to soft tissues or organs (extramedullary disease). About 20 adults with this condition will receive radiation to one tumor site plus …

This study is for people over 60 with multiple myeloma who are getting a stem cell transplant as part of their treatment. Researchers want to see if giving a drug called siltuximab along with a personalized dose of chemotherapy (melphalan) works better than the standard dosing me…

This study tests whether targeted radiation can help control multiple myeloma that remains active after initial CAR-T cell therapy. About 30 adults whose cancer did not fully respond to CAR-T will receive radiation to up to five tumor sites. The goal is to see if this approach ca…

This study tests a combination of four drugs (iberdomide, bortezomib, dexamethasone, and isatuximab) for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this treatment can achieve a very deep response (stringent …

This study tests a new drug called cemsidomide combined with dexamethasone in about 100 adults whose multiple myeloma has returned or stopped responding after at least three prior treatments. The goal is to see if the combination can shrink tumors and control the disease. Partici…

This study is for adults in India with multiple myeloma, a blood cancer that has come back or stopped responding to treatment. Participants have already tried at least three different types of therapy. The goal is to check how safe the drug teclistamab is when used alone in every…

This study is for people newly diagnosed with multiple myeloma or amyloidosis. It tests whether a very sensitive blood test (called MRD) can help decide if a stem cell transplant can be safely delayed. Participants first receive a strong drug combination (Dara-VRD) for 6 cycles. …

This early-phase study tests a new cell therapy called LVIVO-TaVec200 in 36 adults with multiple myeloma that has returned or not responded to standard treatments. The goal is to check if the therapy is safe, find the right dose, and see how long the modified cells stay in the bo…

This study tests an experimental drug called enzomenib (DSP-5336) in people with acute leukemia and certain other blood cancers. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 606 adults will take part, and the study is currently recru…

This study tests an experimental drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that came back after prior therapy. The main goal is to see if the combinations are safe and find the right doses. About 317 adults with this blood ca…

This study tests whether adding linvoseltamab to standard lenalidomide maintenance therapy can eliminate remaining cancer cells (MRD negativity) in people with multiple myeloma. It includes two groups: those with residual disease after initial treatment and those whose disease ha…

This study tests whether the drug elranatamab can lower the chance of multiple myeloma worsening after patients have already received a CAR T-cell therapy called idecabtagene vicleucel (Carvykti). About 32 adults with relapsed or refractory multiple myeloma will take part. The go…

This study offers ongoing treatment with daratumumab for up to 500 adults with multiple myeloma who are already benefiting from it in earlier studies. The goal is to keep providing the drug while monitoring long-term safety, such as serious side effects and infections. Participan…

This early-phase study tests a new type of CAR T-cell therapy for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have returned or not improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cance…

This early-stage study tests a new drug called TQB2934 for people with multiple myeloma, a type of blood cancer. The drug is designed to help the body's immune cells find and kill cancer cells. About 42 adults aged 18 to 75 will receive the drug as a shot under the skin to check …

This early-phase study tests a new injection called JY232 in 9 people with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose. Researchers will also see if the treatment helps shrink the cancer. This …

This study tests whether giving the drug elranatamab before and after a stem cell transplant can better control high-risk multiple myeloma. About 40 adults with newly diagnosed, high-risk myeloma will receive elranatamab to 'purge' cancer cells before transplant and as maintenanc…

This early-phase trial tests a new treatment for multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified in the lab with CRISPR gene editing to target and attack cancer cells. About 30 adults will …

This study tests a new treatment called BCMA-CART, with or without a stem cell transplant, in young adults (18-55) newly diagnosed with multiple myeloma. The goal is to see if it can make the cancer disappear (MRD negative) and keep it away longer. About 50 people will join this …

This early-stage study tests whether combining teclistamab and mezigdomide is safe and works for people with multiple myeloma that has returned or not responded to prior treatments. About 18 adults who have already tried at least two other therapies will take part. The main goal …

This study tests two experimental drugs, etentamig and iberdomide, together in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink the cancer. About 135 participants will receive diffe…

This early-phase study tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. About 138 adults with the disease will take part to see how the drug works in the body and if it he…

This study looks at how HyQvia, a treatment to boost the immune system, is used in real-world clinics for people with multiple myeloma who have a weakened immune system (secondary immunodeficiency). Researchers will track details like dose, infusion speed, and where the treatment…

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This study tests a new PET imaging probe called 68Ga-NB381 in 30 people with or suspected of having multiple myeloma, a type of bone marrow cancer. The probe targets a protein called CD38 found on cancer cells, aiming to improve detection accuracy compared to standard scans. Part…

This study tests a new radioactive tracer called [89Zr]DFO-YS5 for PET scans to find multiple myeloma cells. The tracer targets a protein called CD46 found on some myeloma cells. Researchers want to see if this method is safe and better at detecting cancer than standard scans. Ab…

This study is testing a new blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will check if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans…

This study aims to find multiple myeloma at its earliest, precancerous stage (MGUS) in people at higher risk, including Black adults and close relatives of patients with plasma cell disorders. Researchers will screen up to 1,665 volunteers with a simple blood test. The goal is to…

This study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which targets a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where the tracer goes i…

This study looks at why people with multiple myeloma fall and tests a personalized exercise program to prevent falls. About 60 patients will take part, doing strength and balance training at home using an app. The goal is to reduce fall risk and improve quality of life.

This study tests whether an 8-week home exercise program, done before a stem cell transplant, can improve muscle strength and physical fitness in people with multiple myeloma. Thirty participants will either exercise or continue normal activities. The goal is to see if pre-transp…

This study tests whether adding a non-opioid painkiller (ketorolac) to standard opioid painkillers can reduce the amount of opioids needed after preventive leg surgery. The surgery is done in cancer patients with bone lesions to prevent fractures. About 60 adults will be randomly…

This study tests whether a combination of three drugs (fosaprepitant, tropisetron, and olanzapine) works better than the standard treatment to prevent delayed nausea and vomiting after high-dose chemotherapy in people with multiple myeloma undergoing a stem cell transplant. About…

This study tests if certain preventive treatments can reduce or prevent taste changes (dysgeusia) caused by the drug talquetamab in people with multiple myeloma. About 210 participants will be randomly assigned to different preventive strategies. The goal is to improve quality of…

This study tests a tailored exercise program for 120 adults with multiple myeloma who are about to have a stem cell transplant. The goal is to see if the program reduces fatigue and improves quality of life. Participants will follow a personalized physical activity plan designed …

This study tests whether methylprednisolone works better than dexamethasone at preventing allergic reactions to motixafortide, a drug used to help collect stem cells for transplant in multiple myeloma patients. About 94 adults with multiple myeloma will receive one of the two ste…

This study tests a telemedicine program called FOCUS for people with advanced cancer. The program uses counseling techniques to help with sleep problems, worry, fatigue, and mood. Researchers want to see if using the app improves symptoms and quality of life for 120 patients, esp…

This study tests whether a prehabilitation (prehab) program can help adults aged 60 and older with multiple myeloma maintain physical function before and after a stem cell transplant. Thirty participants will be randomly assigned to either the prehab program or a control group. T…

This study tests whether the drug budesonide can prevent severe diarrhea in people with multiple myeloma who are receiving a stem cell transplant. About 120 adults will be randomly assigned to get either budesonide or a placebo alongside their standard care. The goal is to see if…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home treatment and if it is safe. Participants will receive their usual cancer drugs either at home or in the …

This study compares giving cancer therapy at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment improves quality of life and reduces stress for patients and their families. About 220 participants will be randomly assigned to receive t…

This study tests whether a shorter course of radiation (hypofractionation) is safe for people with multiple myeloma who need pelvic radiation. Instead of the usual 2-3 weeks, participants receive higher daily doses over fewer days. The goal is to find the highest safe dose per se…

This study is for people aged 60 and older with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for CAR-T therapy. Researchers want to see if a special health check (geriatric assessment) before treatment can guide extra support like physical therapy, nutrition …

This study looks at whether adding early palliative care to standard treatment helps people with multiple myeloma or aggressive lymphoma feel better. About 144 patients and their caregivers will be randomly assigned to receive either usual care alone or usual care plus early pall…

This study looks at whether adding a special palliative care program (called PEACE) to usual cancer care can improve quality of life for adults with blood cancers like lymphoma, leukemia, or multiple myeloma who are receiving cell therapy. About 90 participants will be randomly a…

This study looks at whether people with multiple myeloma can and want to join a special exercise program while getting chemotherapy before a stem cell transplant. The program includes both in-person and online sessions to help keep up physical fitness, muscle strength, and qualit…

This study tests whether a home-based program combining gentle physical activity, mindfulness, and telephone health coaching can reduce fatigue and improve quality of life in people aged 65 and older with multiple myeloma. Participants will use a remote monitoring device and rece…

This study follows 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will check for new cancers or other long-term side effects over 15 years. The goal is to understand the lasting safety of this treatment, not …

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like leukemia or lymphoma. The tool helps patients clarify their personal values and shares this with their doctor to guide treatment choices. Researchers want to see if using PR…

This study looks at how certain sugar attachments (N-glycosylation) on abnormal proteins may cause AL amyloidosis, a rare disease where proteins build up and damage organs. Researchers will analyze blood and bone marrow samples from 100 adults with related conditions like AL amyl…

This study looks at how the blood thinner apixaban affects blood clotting in two groups: people newly diagnosed with multiple myeloma and people recovering from total knee replacement. Both groups are at high risk for dangerous blood clots. Researchers want to see if the drug wor…

This study collects and stores blood and tissue samples from 6,000 people with multiple myeloma, smoldering myeloma, plasma cell leukemia, or MGUS. Researchers will use these samples to better understand these diseases and improve future treatments. Participants provide samples a…

This study follows 30,000 people at high risk for multiple myeloma—those with early signs like MGUS or SMM, or with a family history—to learn what makes the disease progress. Researchers will track participants over time to identify risk factors and improve early detection. No tr…

This study aims to understand why multiple myeloma affects African American, Latino, Asian American, and non-Hispanic White patients differently. Researchers will survey 4000 people diagnosed with multiple myeloma in California to learn about factors that may influence the diseas…

This study looks at whether firefighters' exposure to dangerous chemicals on the job raises their risk of developing blood cancers. Researchers will test blood samples from 300 firefighters aged 40-49 with at least 5 years of service to look for early signs of pre-cancerous chang…

This study is creating a database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients direct access to experts and information about support …

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn why some cancers respond differently to treatment. The goal is to develop more effective therapies in the future.

This study interviews 75 people with advanced cancers (like breast, lung, or leukemia) who have been taking daily targeted pills for months or years. Researchers want to hear about their real-life experiences, challenges, and needs. No new treatment is being tested — the goal is …

This study follows about 295 people with multiple myeloma who have already received the cell therapy cilta-cel. The goal is to watch for any delayed side effects, such as new cancers, nerve problems, or serious infections, that may appear months or years after treatment. Particip…

This study follows 700 people with multiple myeloma to see how cannabis (marijuana) use affects their quality of life and symptoms during chemotherapy. Researchers will compare cannabis users to non-users using surveys and medical reports. The goal is to understand potential bene…

This study collects blood, urine, bone marrow, and tissue samples from adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand these diseases, which may lead to new ways to diagnose or treat them. No treatment is given as part of…

This study examines how certain immune cells (monocytes) influence the success of CART cell therapy in people with multiple myeloma. Researchers will analyze blood samples before and after treatment to find factors that predict better response. The goal is to understand why some …

This study is for people with advanced cancer (solid tumors, lymphoma, or multiple myeloma) that has stopped responding to standard treatments. It tests whether giving a targeted drug based on the tumor's specific gene changes can help shrink or control the cancer. The goal is to…

This study looks at a specific gene (IGLV1-44) in 100 people with AL amyloidosis, POEMS syndrome, or multiple myeloma. Researchers want to find unique features in this gene that cause these diseases. The goal is to improve early diagnosis and risk assessment, and to develop new t…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood and solid tumors on PET/CT scans. About 30 people with non-Hodgkin lymphoma, multiple myeloma, or rare histiocytic disorders will receive the agent and then h…

This study tests whether an AI tool can create a personalized list of questions for people with lymphoma or multiple myeloma to ask during their doctor appointments. About 40 participants will use the AI-generated list before a follow-up visit, and researchers will measure how co…

This study is creating a large collection of blood, urine, and tissue samples from up to 10,000 people with amyloid diseases (like multiple myeloma). The goal is to store these samples and health data for future research to better understand these conditions. Participants do not …

This study looks at whether CAR-T therapy, a treatment for certain blood cancers, reduces the protection vaccines give against diseases like measles and mumps. About 45 adults with multiple myeloma or non-Hodgkin lymphoma will have their blood tested before and after CAR-T therap…

This study looks at why some people have low blood cell counts for a long time after CAR-T therapy. Researchers will check for gene changes in blood and bone marrow samples from 82 adults with multiple myeloma or certain lymphomas. The goal is to find which gene changes raise the…

This study is following 1,000 adults with early signs that can lead to multiple myeloma (a type of blood cancer). The goal is to understand why some people's condition gets worse over time while others stay stable. Researchers will use genetic testing and regular checkups to trac…

This study is testing whether a monthly monitoring program called ICOPE can help detect early signs of decline in people over 70 with multiple myeloma. The goal is to prevent loss of independence by catching problems early. About 30 participants will use a smartphone app or chatb…

This study collects information from 1,000 people receiving stem cell transplants for blood diseases at a hospital on the Qinghai-Tibet Plateau. Researchers track recovery, complications, and costs to learn how high altitude affects treatment. The goal is to build a database that…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer and how to prevent, detect, and treat i…

This study is building a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues using surveys and simple physical tests. The goal is to gather information t…

This study aims to collect information from 25 adults with breast, lung, ovarian, multiple myeloma, or AML cancer who are currently receiving treatment. Participants will fill out weekly surveys about their symptoms using a phone, tablet, or computer for at least 12 weeks. The go…

This study looks at how a short-term plant-based diet or supplements (omega-3, curcumin, or probiotics) change butyrate levels in the stool of 200 people with smoldering multiple myeloma or MGUS. Butyrate is a substance made by gut bacteria that may influence health. Participants…

This study looks at whether using a simple early warning score (called NEWS) can help doctors spot when blood cancer patients on strong chemotherapy are getting sicker, and then move them to the intensive care unit (ICU) sooner. The goal is to see if this approach reduces deaths …

This study watches how well the drug combination SVd (selinexor, bortezomib, and dexamethasone) works for adults with multiple myeloma who have already tried 1 to 3 other treatments. It does not give any new drugs—just collects information from regular doctor visits. About 159 pe…

This study watches how older patients (60+) with certain blood cancers handle standard CAR T therapy and how it changes their daily life and thinking skills. It does not give any extra treatment. The goal is to see how many patients can complete all check-ups before their disease…

This study is a large-scale effort to follow 2,300 people diagnosed with various blood diseases, such as leukemia, multiple myeloma, and hemophilia, across multiple hospitals in China. Researchers will collect information from medical records and track participants over time to l…

This study aims to find the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma by studying families where more than one person has the disease. Researchers will collect DNA and blood samples from up to 500 participants, including patients and th…

This study is testing whether daily voice recordings made on a smartphone can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for lymphoma or multiple myeloma. Researchers will ask 20 participants to record their vo…

This study is collecting basic survival and complication information from 2000 people receiving stem cell transplants for blood cancers or immune diseases. The goal is to build a database that helps doctors and researchers better understand long-term outcomes and improve future t…

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers like leukemia and lymphoma, can cause early heart problems. About 60 participants will have heart ultrasounds before and a few days after their CAR-T infusion. The goal is to measure how ofte…

This study is testing a drug called Imuthiol (Zn-DDC) in the lab to see how well it kills blood cancer cells, including those from multiple myeloma and acute leukemia. Researchers will also combine it with other drugs like lenalidomide and pomalidomide to find effective and affor…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a BMS gene-modified cell therapy (like CAR-T). Researchers will test whether the therapy's genes are present in the new tumor. The goal is to understand if the treatment played a role, …

This study aims to see if a new radioactive tracer called 18F-fluciclovine can find multiple myeloma (a type of blood cancer) better than the current tracer. About 60 adults with newly diagnosed or relapsed myeloma will get both types of PET/CT scans to compare them. The goal is …

This study is for people with MGUS or multiple myeloma who are already scheduled for a bone marrow biopsy. Researchers want to see how common sleep apnea is in these patients and whether it changes gene activity in the bone marrow. Participants provide an extra bone marrow sample…

This study enrolls 100 people with relapsed multiple myeloma to analyze their cancer's genetic makeup. Participants provide blood, cheek swab, and tumor samples during routine care. Researchers use advanced sequencing to map gene changes and identify potential new treatments. The…

This study is creating a registry for adults with plasma cell disorders, such as multiple myeloma and amyloidosis. Researchers will collect health information and optional blood samples to learn more about these conditions and support future research. Participants will fill out q…

This study follows 2000 people with multiple myeloma in the West-Occitanie region of France to see how standard treatments work in everyday life, not just in controlled trials. Researchers will track which drugs are used, how patients respond, and how their quality of life change…

This study tests whether cancer drugs that target specific gene changes can shrink tumors or slow cancer growth. It includes adults with advanced solid tumors, multiple myeloma, or certain lymphomas who have no standard treatment options. Participants receive a drug matched to th…

This study looks at why some families have multiple members with blood cancers like lymphoma, leukemia, or myeloma. Researchers will collect genetic and lifestyle information from 3,000 participants to find links between inherited genes and cancer risk. You can join if you have a…

This study collects leftover tissue and fluid samples (like blood or tumor biopsies) from cancer patients at the NIH. The samples are used for research to better understand cancer and develop new tests or treatments. Up to 5,000 adults and children can join, and no extra procedur…

This study is collecting tumor samples from 300 people with high-risk blood or solid cancers, including leukemia, multiple myeloma, and pancreatic cancer. Researchers will use advanced lab tests to create a detailed profile of each tumor. The goal is to see if this information ca…

This study looks at whether a tailored exercise program can slow down the aging process in people aged 50 and older who have survived blood cancers like leukemia or lymphoma. Researchers want to find out how much and what type of exercise is needed to make a difference. The goal …

This study is a large registry that will follow about 2,200 people with multiple myeloma in Germany. Its goal is to collect information on what treatments patients actually receive, how well they work, and how patients feel over time. Participants will have their medical data and…